Evidence map›Paper›PMID 42807958›Full record

ArticleRSC advances2026

Rhenium tricarbonyl coumarin complexes as promising anti-MRSA candidates targeting bacterial biofilms and systemic infection, with reduced resistance development.

Fatlinda Rahmani Mustafaj, Gozde Demirci, Nikola Plackic, Bettina Tran, Aurelien Crochet, Youri Cortat, Nemanja Stanisavljevic, Stefan Salentinig, Aleksandar Pavic, Fabio Zobi

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fatlinda Rahmani MustafajDepartment of Chemistry, University of Fribourg Chemin Du Musée 9 1700 Fribourg Switzerland fabio.zobi@unifr.ch.
Gozde DemirciDepartment of Chemistry, University of Fribourg Chemin Du Musée 9 1700 Fribourg Switzerland fabio.zobi@unifr.ch.
Nikola PlackicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade Vojvode Stepe 444a 11042 Belgrade 152 Serbia.ORCID https://orcid.org/0009-0005-3466-6841
Bettina TranDepartment of Chemistry, University of Fribourg Chemin Du Musée 9 1700 Fribourg Switzerland fabio.zobi@unifr.ch.
Aurelien CrochetDepartment of Chemistry, University of Fribourg Chemin Du Musée 9 1700 Fribourg Switzerland fabio.zobi@unifr.ch.ORCID https://orcid.org/0000-0002-4763-2764
Youri CortatDepartment of Chemistry, University of Fribourg Chemin Du Musée 9 1700 Fribourg Switzerland fabio.zobi@unifr.ch.
Nemanja StanisavljevicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade Vojvode Stepe 444a 11042 Belgrade 152 Serbia.
Stefan SalentinigDepartment of Chemistry, University of Fribourg Chemin Du Musée 9 1700 Fribourg Switzerland fabio.zobi@unifr.ch.ORCID https://orcid.org/0000-0002-7541-2734
Aleksandar PavicInstitute of Molecular Genetics and Genetic Engineering, University of Belgrade Vojvode Stepe 444a 11042 Belgrade 152 Serbia.
Fabio ZobiDepartment of Chemistry, University of Fribourg Chemin Du Musée 9 1700 Fribourg Switzerland fabio.zobi@unifr.ch.ORCID https://orcid.org/0000-0002-9077-7184

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) is a major threat to public health, causing serious issues in the successful prevention and treatment of persistent diseases. Transition metal complexes are being intensively researched as promising alternatives to traditional antibiotics for the development of novel antimicrobial therapies. In our ongoing efforts to identify safe and effective rhenium-based antibiotics, we have prepared a family of compounds bearing derivatives of thiazolohydrazinylidene-chroman-2,4-diones. Two compounds were identified as being active and nontoxic

Identifiers

PMID42807958
PMCPMC13618350

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.